Technologies
This technology is a therapeutic method to reduce plasma triglycerides commonly elevated in obesity-induced metabolic syndrome.
Obesity can result in a serious condition called metabolic syndrome. A core component of the syndrome is hypertriglyceridemia, or excess plasma triglycerides, which is a risk factor for coronary heart disease. Current therapies for hypertriglyceridemia include fibrate, omega-3 fatty acids, bile acid sequestrants, niacin, and statins. These treatments lower triglyceride levels insufficiently and the persistence of high triglyceride levels leaves patients at risk of a heart attack. Thus, there is an ongoing need to develop additional strategies that efficiently decrease triglyceride levels in alternative and complementary ways to current approaches.
This technology is a method for efficiently reducing the levels of plasma triglycerides and serum apolipoprotein C3 (ApoC3) by inhibiting the gamma-secretase complex. Gamma-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the low-density lipoprotein receptor. As such, small molecule or oligonucleotide gamma-secretase inhibitors could be used as potential treatment options for targeting gamma-secretase in patients, leading to improved glucose metabolism. This therapeutic strategy provides an effective method for patients with metabolic disorders such as diabetes, obesity, and hypertriglyceridemia to reduce their plasma triglyceride levels.
This technology has been validated in mouse models.
IR CU14176
Licensing Contact: Cynthia Lang